Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
Charlie Zhou, Head of Portfolio Strategy at Ouro Medicines, shared a post on LinkedIn about the recent article he and his colleagues co-authored, adding:
“It’s been a privilege to collaborate with some of the preeminent experts in autoimmune cytopenias on this review examining the potential of immune reset therapies to change the treatment landscape for these debilitating conditions.”
Title: Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies
Authors: David J. Kuter, Sigbjørn Berentsen, Nichola Cooper, Lei Zhang, Jun Shi, Yunfei Chen, Lele Zhang, Charlie Zhou, Yanrong Wang, Jaideep S. Dudani, Neelufar Mozaffarian
Read the Full Article on Blood Reviews
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers